Taylor S H, Silke B
J Cardiovasc Pharmacol. 1985;7 Suppl 2:S80-9. doi: 10.1097/00005344-198507002-00016.
Beta-blocking drugs were specifically introduced for the treatment of exercise-induced angina pectoris. Their therapeutic utility in this specific presentation of coronary insufficiency is undoubted. However, since they were introduced, evolution of the pathological, haemodynamic, and electrophysiological understanding of the disease syndrome has undergone considerable reappraisal, in no small measure owing to the physiological tool that these drugs have furnished. Their influence on the various aspects of the syndrome of exercise-induced ischaemic myocardial pain is widely known. The physiological conflict posed by unopposed blockade of one sympathetic outflow pathway remains the source of many of their clinical disadvantages. Many important questions directly related to their therapeutic use remain unanswered. The potential benefits and hazards of their long-term administration in patients with advanced coronary heart disease remains to be established.
β受体阻滞剂专门用于治疗运动诱发的心绞痛。它们在这种特定形式的冠状动脉供血不足中的治疗效用是毋庸置疑的。然而，自从它们被引入以来，由于这些药物所提供的生理学工具，对该疾病综合征的病理、血流动力学和电生理学理解的演变经历了相当大的重新评估。它们对运动诱发的缺血性心肌疼痛综合征各个方面的影响广为人知。对一条交感神经流出途径的无对抗性阻断所造成的生理冲突仍然是它们许多临床缺点的根源。许多与它们的治疗用途直接相关的重要问题仍未得到解答。它们在晚期冠心病患者中长期给药的潜在益处和风险仍有待确定。
